H.C. Wainwright lowered the firm’s price target on Celldex (CLDX) to $42 from $50 and keeps a Buy rating on the shares. The company announced mixed topline results from its Phase 2 trial assessing barzolvolimab in eosinophilic esophagitis, the analyst tells investors in a research note. The firm removing eosinophilic esophagitis from its barzolvolimab projected indications.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex price target lowered to $38 from $44 at Wells Fargo
- Celldex’s Promising Pipeline and Financial Stability Justify Buy Rating Despite Recent Setback
- Closing Bell Movers: La-Z-Boy down 24% after earnings miss
- Celldex down 12.5% at $21.01 after barzolvolimab study update
- Celldex Halts Barzolvolimab Development for EoE